The stock of Applied Genetic Technologies Corp (NASDAQ:AGTC) is a huge mover today! About 69,682 shares traded hands. Applied Genetic Technologies Corp (NASDAQ:AGTC) has declined 58.10% since April 5, 2016 and is downtrending. It has underperformed by 60.05% the S&P500.
The move comes after 9 months positive chart setup for the $132.02 million company. It was reported on Nov, 7 by Barchart.com. We have $9.65 PT which if reached, will make NASDAQ:AGTC worth $42.25 million more.
Applied Genetic Technologies Corp (NASDAQ:AGTC) Ratings Coverage
Out of 8 analysts covering Applied Genetic (NASDAQ:AGTC), 3 rate it a “Buy”, 0 “Sell”, while 5 “Hold”. This means 38% are positive. Applied Genetic has been the topic of 14 analyst reports since July 22, 2015 according to StockzIntelligence Inc. The stock of Applied Genetic Technologies Corp (NASDAQ:AGTC) has “Market Perform” rating given on Tuesday, September 13 by Wells Fargo. The rating was downgraded by Cantor Fitzgerald on Tuesday, September 13 to “Hold”. Chardan Capital Markets initiated the shares of AGTC in a report on Wednesday, July 22 with “Buy” rating. The stock of Applied Genetic Technologies Corp (NASDAQ:AGTC) has “Neutral” rating given on Tuesday, September 13 by Roth Capital. As per Friday, March 18, the company rating was initiated by Janney Capital. The stock of Applied Genetic Technologies Corp (NASDAQ:AGTC) earned “Outperform” rating by BMO Capital Markets on Tuesday, September 13. TH Capital downgraded the shares of AGTC in a report on Tuesday, September 13 to “Neutral” rating. The firm has “Outperform” rating given on Tuesday, September 13 by Wedbush. On Sunday, August 30 the stock rating was maintained by Chardan Capital Markets with “Buy”. The stock has “Sell” rating given by Janney Capital on Tuesday, September 13.
According to Zacks Investment Research, “Applied Genetic Technologies Corporation is a clinical-stage biotechnology company. It develops gene therapy products for inherited orphan ophthalmology diseases. Its lead product candidates in the preclinical stage include treatments for X-linked retinoschisis, Achromatopsia, and X-linked retinitis pigmentosa, which are diseases of the eye caused by mutations in single genes. Applied Genetic Technologies Corporation is headquartered in Alachua, Florida.”
Insitutional Activity: The institutional sentiment decreased to 1.66 in Q2 2016. Its down 0.17, from 1.83 in 2016Q1. The ratio fall, as 6 funds sold all Applied Genetic Technologies Corp shares owned while 26 reduced positions. 11 funds bought stakes while 42 increased positions. They now own 10.69 million shares or 1.50% more from 10.53 million shares in 2016Q1.
Allianz Asset Management Ag has 83,840 shares for 0% of their US portfolio. Tower Rech Limited Company (Trc) has 863 shares for 0% of their US portfolio. Goldman Sachs Grp accumulated 50,868 shares or 0% of the stock. Clearbridge Invests Ltd Company has invested 0% of its portfolio in Applied Genetic Technologies Corp (NASDAQ:AGTC). Teachers Incorporated holds 0% of its portfolio in Applied Genetic Technologies Corp (NASDAQ:AGTC) for 20,060 shares. Savings Bank Of Montreal Can, a Ontario – Canada-based fund reported 40,066 shares. Magee Thomson Inv Prtnrs Ltd owns 44 shares or 0% of their US portfolio. Nationwide Fund Advsr last reported 0% of its portfolio in the stock. Moreover, Mufg Americas Corp has 0% invested in Applied Genetic Technologies Corp (NASDAQ:AGTC) for 1,100 shares. Blackrock Japan Limited holds 0% or 1,147 shares in its portfolio. Acadian Asset Management Ltd Company has 498,825 shares for 0.04% of their US portfolio. Emerald Advisers Incorporated Pa has 290,784 shares for 0.2% of their US portfolio. State Bank Of America Corporation De holds 0% or 9,365 shares in its portfolio. Jennison Assoc Ltd Liability Com reported 683,451 shares or 0.01% of all its holdings. Altrinsic Ltd Liability Corp owns 199,000 shares or 0.08% of their US portfolio.
Insider Transactions: Since September 16, 2016, the stock had 3 buys, and 1 sale for $119,496 net activity. Potter Stephen W also bought $12,446 worth of Applied Genetic Technologies Corp (NASDAQ:AGTC) on Friday, September 16. Shares for $87,500 were bought by BULLOCK LAWRENCE E on Monday, September 19. Shearman Mark S bought $26,602 worth of Applied Genetic Technologies Corp (NASDAQ:AGTC) on Thursday, September 22. Chulay Jeffrey D. sold $7,052 worth of stock.
More recent Applied Genetic Technologies Corp (NASDAQ:AGTC) news were published by: Fool.com which released: “Why Applied Genetic Technologies Corp. Is Tanking Today” on September 13, 2016. Also Marketwatch.com published the news titled: “Applied Genetic Technologies Corp.” on April 22, 2014. Globenewswire.com‘s news article titled: “AGTC Files Investigational New Drug Application for the Treatment of …” with publication date: October 19, 2016 was also an interesting one.
AGTC Company Profile
Applied Genetic Technologies Corporation, incorporated on October 24, 2003, is a clinical-stage biotechnology company. The Firm develops gene therapy products designed to manage the lives of patients with severe diseases in ophthalmology. As of March 31, 2016, its product candidates included treatments for X-linked retinoschisis (XLRS), over two forms of achromatopsia (ACHM) and X-linked retinitis pigmentosa (XLRP). As of March 31, 2016, the Company was engaged in developing three discovery programs, targeting three indications based on the Company’s adeno-associated virus (AAV) vector technologies. The Firm is also developing Alpha-1 Antitrypsin Deficiency (Alpha 1).
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.